Pain relief in outpatient knee arthroscopy
This study tests a numbing medicine called prilocaine, which is given in the spine to block pain during knee arthroscopy. It looks at how well it works and its safety for people going home the same day.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are having outpatient knee arthroscopy (knee surgery where you go home the same day).
- You are not a child (this study is for adults).
- You are not staying in the hospital overnight for your surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving bupivacaine (a numbing medicine) around the time of knee arthroscopy can reduce pain at the surgery sites and help you move your knee better after the operation.
This study compares two ways to manage pain after knee arthroscopy surgery. One group gets a special numbing injection around the knee (TIPS block), and the other gets standard pain medicine through an IV.
This study compares two types of nerve blocks (iPACK and adductor canal block) to see which provides better pain relief after arthroscopic knee surgery. It may help you have less pain and recover faster.
This study tests a new way to deliver pain medication during and after knee replacement surgery. Researchers compare injecting a long-acting numbing medicine (EXPAREL) directly into the knee joint versus spreading it through the surgical area, to see which method works better for pain control.
This trial checks how a numbing medicine moves during a common knee block for surgery. It may help doctors improve pain control after knee operations.
This trial tests whether adding dexmedetomidine to a numbing injection (bupivacaine) inside the knee joint provides better pain relief after arthroscopic ACL reconstruction. It aims to help patients recover more comfortably after surgery.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.